Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Hepatocellular Carcinoma

Treatments: Other: Retrospective analysis of already archived samples

Study type: Observational

Funder types: Industry

Identifiers

NCT00911196

111726

Details and patient eligibility

About

Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out, and the correlation of expression with disease variables and clinical outcome will be assessed. This will be done retrospectively using archived hepatocellular carcinoma tissue samples.

Enrollment: 200 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient has pathologically proven hepatocellular carcinoma (any stage)
• All the data required are available from patient's records

Exclusion criteria

N/A

Trial design

200 participants in 1 patient group

Group A

Treatment:

Other: Retrospective analysis of already archived samples